Patents by Inventor Kenneth C. Keiler

Kenneth C. Keiler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBACTERIAL COMPOUNDS
    Publication number: 20230183203
    Abstract: The present application provides antibiotic compounds, as well as pharmaceutical compositions comprising these compounds, and methods of treating bacterial infections using these compounds
    Type: Application
    Filed: May 27, 2021
    Publication date: June 15, 2023
    Inventors: Kenneth C. Keiler, John N. Alumasa, Sarah Ellen Ades
  • METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
    Publication number: 20230109833
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 13, 2023
    Applicants: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
    Patent number: 11505533
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 22, 2022
    Assignees: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
    Publication number: 20200361882
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 19, 2020
    Applicants: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • Antibacterial and plasmid elimination agents
    Patent number: 10597735
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vive by the addition of the peptides.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: March 24, 2020
    Assignee: The Penn State Research Foundation
    Inventors: Kenneth C Keiler, Stephen J Benkovic
  • ANTIBACTERIAL AND PLASMID ELIMINATION AGENTS
    Publication number: 20170096717
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vive by the addition of the peptides.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 6, 2017
    Inventors: KENNETH C. KEILER, Stephen J. Benkovic
  • Antibacterial and plasmid elimination agents
    Patent number: 9562257
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vivo by the addition of the peptides.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 7, 2017
    Assignee: The Penn State Research Foundation
    Inventors: Kenneth C Keiler, Stephen J Benkovic
  • ANTIBACTERIAL AND PLASMID ELIMINATION AGENTS
    Publication number: 20140187443
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vivo by the addition of the peptides.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicant: The Penn State Research Foundation
    Inventors: Kenneth C. KEILER, Stephen J. Benkovic
  • Antibacterial and plasmid elimination agents
    Patent number: 8637267
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vivo by the addition of the peptides.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: January 28, 2014
    Assignee: The Penn State Research Foundation
    Inventors: Kenneth C. Keiler, Stephen J. Benkovic
  • ANTIBACTERIAL AND PLASMID ELIMINATION AGENTS
    Publication number: 20110288008
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vivo by the addition of the peptides.
    Type: Application
    Filed: June 6, 2007
    Publication date: November 24, 2011
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Kenneth C. Keiler, Stephen J. Benkovic
  • ANTIBACTERIAL AND PLASMID ELIMINATION AGENTS
    Publication number: 20090143241
    Abstract: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence genes. The molecular target of each cyclic peptide is in the tmRNA pathway and the tmRNA pathway is inhibited in vitro and in vivo by the addition of the peptides.
    Type: Application
    Filed: April 28, 2008
    Publication date: June 4, 2009
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Kenneth C. Keiler, Stephen J. Benkovic